http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 28 May 2026 09:10:51 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Equity+Offerings/Medicenna+raises+CDN%244.44+million+in+public+offering+of+units/26562377.html <p>Medicenna Therapeutics Corp. (TSX: MDNA) completed a public offering of 8,880,000 units at CDN$0.50 per unit, raising approximately CDN$4.44 million in gross proceeds before expenses.</p> <p>Each unit consists of one common share and one-half of a common share purchase warrant. The warrants allow holders to purchase additional shares at CDN$0.65 each for three years following the closing date.</p> <p>Bloom Burton Securities Inc. served as the sole agent for the offering under an agency agreement dated May 21, 2026. The company issued 450,100 compensation warrants to the agent, exercisable at CDN$0.50 per share for two years.</p> <p>The offering was conducted under a prospectus supplement http://www.streetinsider.com/Equity+Offerings/Medicenna+raises+CDN%244.44+million+in+public+offering+of+units/26562377.html Thu, 28 May 2026 09:10:51 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Equity+Offerings/Medicenna+raises+CDN%244.44+million+in+public+offering+of+units/26562377.html <p>Medicenna Therapeutics Corp. (TSX: MDNA) completed a public offering of 8,880,000 units at CDN$0.50 per unit, raising approximately CDN$4.44 million in gross proceeds before expenses.</p> <p>Each unit consists of one common share and one-half of a common share purchase warrant. The warrants allow holders to purchase additional shares at CDN$0.65 each for three years following the closing date.</p> <p>Bloom Burton Securities Inc. served as the sole agent for the offering under an agency agreement dated May 21, 2026. The company issued 450,100 compensation warrants to the agent, exercisable at CDN$0.50 per share for two years.</p> <p>The offering was conducted under a prospectus supplement http://www.streetinsider.com/Equity+Offerings/Medicenna+raises+CDN%244.44+million+in+public+offering+of+units/26562377.html Thu, 28 May 2026 09:10:51 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Equity+Offerings/Medicenna+raises+CDN%244.44+million+in+public+offering+of+units/26562377.html <p>Medicenna Therapeutics Corp. (TSX: MDNA) completed a public offering of 8,880,000 units at CDN$0.50 per unit, raising approximately CDN$4.44 million in gross proceeds before expenses.</p> <p>Each unit consists of one common share and one-half of a common share purchase warrant. The warrants allow holders to purchase additional shares at CDN$0.65 each for three years following the closing date.</p> <p>Bloom Burton Securities Inc. served as the sole agent for the offering under an agency agreement dated May 21, 2026. The company issued 450,100 compensation warrants to the agent, exercisable at CDN$0.50 per share for two years.</p> <p>The offering was conducted under a prospectus supplement http://www.streetinsider.com/Equity+Offerings/Medicenna+raises+CDN%244.44+million+in+public+offering+of+units/26562377.html Thu, 28 May 2026 09:10:51 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Press+Releases/Medicenna+Announces+Closing+of+Public+Offering+of+Units+Raising+CDN%244.44+Million+to+Support+Lead+Programs/26562375.html <p align="center" style="padding-left:0pt;"><strong>NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES</strong></p> <p align="justify">TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, is pleased to announce the closing of its previously announced marketed public offering of units (the “Units”) of the Company at a price to the public of CDN$0.50 per Unit (the “Offering”), for aggregate gross proceeds to the Company of approximately CDN$4.44 million, before deducting Offering expenses and excluding any proceeds http://www.streetinsider.com/Press+Releases/Medicenna+Announces+Closing+of+Public+Offering+of+Units+Raising+CDN%244.44+Million+to+Support+Lead+Programs/26562375.html Thu, 28 May 2026 09:10:00 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Press+Releases/Medicenna+Announces+Closing+of+Public+Offering+of+Units+Raising+CDN%244.44+Million+to+Support+Lead+Programs/26562375.html <p align="center" style="padding-left:0pt;"><strong>NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES</strong></p> <p align="justify">TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, is pleased to announce the closing of its previously announced marketed public offering of units (the “Units”) of the Company at a price to the public of CDN$0.50 per Unit (the “Offering”), for aggregate gross proceeds to the Company of approximately CDN$4.44 million, before deducting Offering expenses and excluding any proceeds http://www.streetinsider.com/Press+Releases/Medicenna+Announces+Closing+of+Public+Offering+of+Units+Raising+CDN%244.44+Million+to+Support+Lead+Programs/26562375.html Thu, 28 May 2026 09:10:00 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Press+Releases/Medicenna+Announces+Closing+of+Public+Offering+of+Units+Raising+CDN%244.44+Million+to+Support+Lead+Programs/26562375.html <p align="center" style="padding-left:0pt;"><strong>NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES</strong></p> <p align="justify">TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, is pleased to announce the closing of its previously announced marketed public offering of units (the “Units”) of the Company at a price to the public of CDN$0.50 per Unit (the “Offering”), for aggregate gross proceeds to the Company of approximately CDN$4.44 million, before deducting Offering expenses and excluding any proceeds http://www.streetinsider.com/Press+Releases/Medicenna+Announces+Closing+of+Public+Offering+of+Units+Raising+CDN%244.44+Million+to+Support+Lead+Programs/26562375.html Thu, 28 May 2026 09:10:00 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Globe+Newswire/Medicenna+Announces+Closing+of+Public+Offering+of+Units+Raising+CDN%244.44+Million+to+Support+Lead+Programs/26562375.html <p align="center" style="padding-left:0pt;"><strong>NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES</strong></p> <p align="justify">TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, is pleased to announce the closing of its previously announced marketed public offering of units (the “Units”) of the Company at a price to the public of CDN$0.50 per Unit (the “Offering”), for aggregate gross proceeds to the Company of approximately CDN$4.44 million, before deducting Offering expenses and excluding any proceeds http://www.streetinsider.com/Globe+Newswire/Medicenna+Announces+Closing+of+Public+Offering+of+Units+Raising+CDN%244.44+Million+to+Support+Lead+Programs/26562375.html Thu, 28 May 2026 09:10:00 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Globe+Newswire/Medicenna+Announces+Closing+of+Public+Offering+of+Units+Raising+CDN%244.44+Million+to+Support+Lead+Programs/26562375.html <p align="center" style="padding-left:0pt;"><strong>NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES</strong></p> <p align="justify">TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, is pleased to announce the closing of its previously announced marketed public offering of units (the “Units”) of the Company at a price to the public of CDN$0.50 per Unit (the “Offering”), for aggregate gross proceeds to the Company of approximately CDN$4.44 million, before deducting Offering expenses and excluding any proceeds http://www.streetinsider.com/Globe+Newswire/Medicenna+Announces+Closing+of+Public+Offering+of+Units+Raising+CDN%244.44+Million+to+Support+Lead+Programs/26562375.html Thu, 28 May 2026 09:10:00 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Globe+Newswire/Medicenna+Announces+Closing+of+Public+Offering+of+Units+Raising+CDN%244.44+Million+to+Support+Lead+Programs/26562375.html <p align="center" style="padding-left:0pt;"><strong>NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES</strong></p> <p align="justify">TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, is pleased to announce the closing of its previously announced marketed public offering of units (the “Units”) of the Company at a price to the public of CDN$0.50 per Unit (the “Offering”), for aggregate gross proceeds to the Company of approximately CDN$4.44 million, before deducting Offering expenses and excluding any proceeds http://www.streetinsider.com/Globe+Newswire/Medicenna+Announces+Closing+of+Public+Offering+of+Units+Raising+CDN%244.44+Million+to+Support+Lead+Programs/26562375.html Thu, 28 May 2026 09:10:00 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Press+Releases/Medicenna+Announces+the+Filing+of+its+Prospectus+Supplement+and+Investment+Term+Sheet/26538429.html <p align="center"><strong>NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES</strong></p> <p align="justify">TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the ”Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that, in connection with its previously announced marketed public offering (the “Offering”) of units of the Company (“Units”), it has filed a prospectus supplement (the “Prospectus Supplement”) to the Company’s existing short form base shelf prospectus dated June 4, 2025 (the ”Base Shelf Prospectus”) with the http://www.streetinsider.com/Press+Releases/Medicenna+Announces+the+Filing+of+its+Prospectus+Supplement+and+Investment+Term+Sheet/26538429.html Fri, 22 May 2026 07:00:00 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Press+Releases/Medicenna+Announces+the+Filing+of+its+Prospectus+Supplement+and+Investment+Term+Sheet/26538429.html <p align="center"><strong>NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES</strong></p> <p align="justify">TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the ”Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that, in connection with its previously announced marketed public offering (the “Offering”) of units of the Company (“Units”), it has filed a prospectus supplement (the “Prospectus Supplement”) to the Company’s existing short form base shelf prospectus dated June 4, 2025 (the ”Base Shelf Prospectus”) with the http://www.streetinsider.com/Press+Releases/Medicenna+Announces+the+Filing+of+its+Prospectus+Supplement+and+Investment+Term+Sheet/26538429.html Fri, 22 May 2026 07:00:00 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Press+Releases/Medicenna+Announces+the+Filing+of+its+Prospectus+Supplement+and+Investment+Term+Sheet/26538429.html <p align="center"><strong>NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES</strong></p> <p align="justify">TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the ”Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that, in connection with its previously announced marketed public offering (the “Offering”) of units of the Company (“Units”), it has filed a prospectus supplement (the “Prospectus Supplement”) to the Company’s existing short form base shelf prospectus dated June 4, 2025 (the ”Base Shelf Prospectus”) with the http://www.streetinsider.com/Press+Releases/Medicenna+Announces+the+Filing+of+its+Prospectus+Supplement+and+Investment+Term+Sheet/26538429.html Fri, 22 May 2026 07:00:00 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Globe+Newswire/Medicenna+Announces+the+Filing+of+its+Prospectus+Supplement+and+Investment+Term+Sheet/26538429.html <p align="center"><strong>NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES</strong></p> <p align="justify">TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the ”Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that, in connection with its previously announced marketed public offering (the “Offering”) of units of the Company (“Units”), it has filed a prospectus supplement (the “Prospectus Supplement”) to the Company’s existing short form base shelf prospectus dated June 4, 2025 (the ”Base Shelf Prospectus”) with the http://www.streetinsider.com/Globe+Newswire/Medicenna+Announces+the+Filing+of+its+Prospectus+Supplement+and+Investment+Term+Sheet/26538429.html Fri, 22 May 2026 07:00:00 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Globe+Newswire/Medicenna+Announces+the+Filing+of+its+Prospectus+Supplement+and+Investment+Term+Sheet/26538429.html <p align="center"><strong>NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES</strong></p> <p align="justify">TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the ”Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that, in connection with its previously announced marketed public offering (the “Offering”) of units of the Company (“Units”), it has filed a prospectus supplement (the “Prospectus Supplement”) to the Company’s existing short form base shelf prospectus dated June 4, 2025 (the ”Base Shelf Prospectus”) with the http://www.streetinsider.com/Globe+Newswire/Medicenna+Announces+the+Filing+of+its+Prospectus+Supplement+and+Investment+Term+Sheet/26538429.html Fri, 22 May 2026 07:00:00 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Globe+Newswire/Medicenna+Announces+the+Filing+of+its+Prospectus+Supplement+and+Investment+Term+Sheet/26538429.html <p align="center"><strong>NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES</strong></p> <p align="justify">TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the ”Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that, in connection with its previously announced marketed public offering (the “Offering”) of units of the Company (“Units”), it has filed a prospectus supplement (the “Prospectus Supplement”) to the Company’s existing short form base shelf prospectus dated June 4, 2025 (the ”Base Shelf Prospectus”) with the http://www.streetinsider.com/Globe+Newswire/Medicenna+Announces+the+Filing+of+its+Prospectus+Supplement+and+Investment+Term+Sheet/26538429.html Fri, 22 May 2026 07:00:00 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Equity+Offerings/Medicenna+finalizes+terms+for+public+offering+at+%240.50+per+unit/26517081.html <p>Medicenna Therapeutics Corp. (TSX: MDNA) announced it has finalized terms for its previously announced public offering of securities. The clinical-stage immunotherapy company will offer units at $0.50 each, with each unit consisting of one common share and half of one warrant.</p> <p>Each warrant allows the holder to purchase one common share at $0.65 until three years after the offering closes. Bloom Burton Securities Inc. is serving as sole agent for the offering.</p> <p>The offering is expected to close around May 27, 2026, pending regulatory and stock exchange approvals. Medicenna plans to use proceeds primarily for clinical and regulatory development of its lead http://www.streetinsider.com/Equity+Offerings/Medicenna+finalizes+terms+for+public+offering+at+%240.50+per+unit/26517081.html Tue, 19 May 2026 07:00:36 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Equity+Offerings/Medicenna+finalizes+terms+for+public+offering+at+%240.50+per+unit/26517081.html <p>Medicenna Therapeutics Corp. (TSX: MDNA) announced it has finalized terms for its previously announced public offering of securities. The clinical-stage immunotherapy company will offer units at $0.50 each, with each unit consisting of one common share and half of one warrant.</p> <p>Each warrant allows the holder to purchase one common share at $0.65 until three years after the offering closes. Bloom Burton Securities Inc. is serving as sole agent for the offering.</p> <p>The offering is expected to close around May 27, 2026, pending regulatory and stock exchange approvals. Medicenna plans to use proceeds primarily for clinical and regulatory development of its lead http://www.streetinsider.com/Equity+Offerings/Medicenna+finalizes+terms+for+public+offering+at+%240.50+per+unit/26517081.html Tue, 19 May 2026 07:00:36 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Equity+Offerings/Medicenna+finalizes+terms+for+public+offering+at+%240.50+per+unit/26517081.html <p>Medicenna Therapeutics Corp. (TSX: MDNA) announced it has finalized terms for its previously announced public offering of securities. The clinical-stage immunotherapy company will offer units at $0.50 each, with each unit consisting of one common share and half of one warrant.</p> <p>Each warrant allows the holder to purchase one common share at $0.65 until three years after the offering closes. Bloom Burton Securities Inc. is serving as sole agent for the offering.</p> <p>The offering is expected to close around May 27, 2026, pending regulatory and stock exchange approvals. Medicenna plans to use proceeds primarily for clinical and regulatory development of its lead http://www.streetinsider.com/Equity+Offerings/Medicenna+finalizes+terms+for+public+offering+at+%240.50+per+unit/26517081.html Tue, 19 May 2026 07:00:36 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Press+Releases/Medicenna+Announces+the+Finalization+of+the+Terms+of+its+Public+Offering+of+Securities/26517042.html <p align="center"><em>Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+</em><strong><em>1</em></strong></p> <p align="justify">TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that it has finalized the terms of its previously-announced marketed underwritten public offering of securities of the Company, being an offering of units of the Company (the “Units”) at a price to the public of $0.50 per Unit (the “Offering”). Each Unit will be comprised http://www.streetinsider.com/Press+Releases/Medicenna+Announces+the+Finalization+of+the+Terms+of+its+Public+Offering+of+Securities/26517042.html Tue, 19 May 2026 07:00:00 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Press+Releases/Medicenna+Announces+the+Finalization+of+the+Terms+of+its+Public+Offering+of+Securities/26517042.html <p align="center"><em>Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+</em><strong><em>1</em></strong></p> <p align="justify">TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that it has finalized the terms of its previously-announced marketed underwritten public offering of securities of the Company, being an offering of units of the Company (the “Units”) at a price to the public of $0.50 per Unit (the “Offering”). Each Unit will be comprised http://www.streetinsider.com/Press+Releases/Medicenna+Announces+the+Finalization+of+the+Terms+of+its+Public+Offering+of+Securities/26517042.html Tue, 19 May 2026 07:00:00 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Press+Releases/Medicenna+Announces+the+Finalization+of+the+Terms+of+its+Public+Offering+of+Securities/26517042.html <p align="center"><em>Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+</em><strong><em>1</em></strong></p> <p align="justify">TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that it has finalized the terms of its previously-announced marketed underwritten public offering of securities of the Company, being an offering of units of the Company (the “Units”) at a price to the public of $0.50 per Unit (the “Offering”). Each Unit will be comprised http://www.streetinsider.com/Press+Releases/Medicenna+Announces+the+Finalization+of+the+Terms+of+its+Public+Offering+of+Securities/26517042.html Tue, 19 May 2026 07:00:00 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Globe+Newswire/Medicenna+Announces+the+Finalization+of+the+Terms+of+its+Public+Offering+of+Securities/26517042.html <p align="center"><em>Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+</em><strong><em>1</em></strong></p> <p align="justify">TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that it has finalized the terms of its previously-announced marketed underwritten public offering of securities of the Company, being an offering of units of the Company (the “Units”) at a price to the public of $0.50 per Unit (the “Offering”). Each Unit will be comprised http://www.streetinsider.com/Globe+Newswire/Medicenna+Announces+the+Finalization+of+the+Terms+of+its+Public+Offering+of+Securities/26517042.html Tue, 19 May 2026 07:00:00 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Globe+Newswire/Medicenna+Announces+the+Finalization+of+the+Terms+of+its+Public+Offering+of+Securities/26517042.html <p align="center"><em>Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+</em><strong><em>1</em></strong></p> <p align="justify">TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that it has finalized the terms of its previously-announced marketed underwritten public offering of securities of the Company, being an offering of units of the Company (the “Units”) at a price to the public of $0.50 per Unit (the “Offering”). Each Unit will be comprised http://www.streetinsider.com/Globe+Newswire/Medicenna+Announces+the+Finalization+of+the+Terms+of+its+Public+Offering+of+Securities/26517042.html Tue, 19 May 2026 07:00:00 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Globe+Newswire/Medicenna+Announces+the+Finalization+of+the+Terms+of+its+Public+Offering+of+Securities/26517042.html <p align="center"><em>Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+</em><strong><em>1</em></strong></p> <p align="justify">TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that it has finalized the terms of its previously-announced marketed underwritten public offering of securities of the Company, being an offering of units of the Company (the “Units”) at a price to the public of $0.50 per Unit (the “Offering”). Each Unit will be comprised http://www.streetinsider.com/Globe+Newswire/Medicenna+Announces+the+Finalization+of+the+Terms+of+its+Public+Offering+of+Securities/26517042.html Tue, 19 May 2026 07:00:00 -0400 MDNA MDNAF O.48242534 http://www.streetinsider.com/Equity+Offerings/Medicenna+launches+public+offering+to+fund+clinical+programs/26485672.html <p>Medicenna Therapeutics Corp. (TSX: MDNA) announced the launch of a marketed public offering of securities, according to a press release statement. The clinical-stage immunotherapy company focuses on developing treatments targeting cancer and autoimmune diseases.</p> <p>Bloom Burton Securities Inc. will act as sole agent for the offering on a best efforts agency basis. The specific type of securities, pricing, offering size and final terms will be determined through negotiations between Medicenna and Bloom Burton based on market conditions.</p> <p>The company plans to use net proceeds primarily to advance clinical and regulatory development of its lead programs, including MDNA11 and MDNA113, along with working http://www.streetinsider.com/Equity+Offerings/Medicenna+launches+public+offering+to+fund+clinical+programs/26485672.html Wed, 13 May 2026 16:01:17 -0400 MDNA MDNAF O.48242534